Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416142 | 0.90 | GRIN2C (0.55) | GRIN2CKMT2AMEN1TP53MTNR1B | |
| SCHEMBL4414980 | 0.83 | KMT2A (0.60) | GRIN2CKMT2AMEN1TP53MTNR1B | |
| SCHEMBL4424375 | 0.81 | HTT (0.71) | GRIN2CKMT2AMAPTMTNR1BLMNA | |
| SCHEMBL4552564 | 0.81 | GRIN2C (0.64) | GRIN2CKMT2AMEN1TP53MTNR1B | |
| SCHEMBL7899470 | 0.79 | GRIN2C (1.00) | GRIN2CTP53 | |
| SCHEMBL4416149 | 0.77 | MTNR1B (0.45) | GRIN2CKMT2AMEN1TP53MTNR1B | |
| SCHEMBL4413447 | 0.76 | KMT2A (0.55) | GRIN2CKMT2AMEN1TP53LMNA | |
| SCHEMBL4416765 | 0.75 | KMT2A (0.51) | GRIN2CKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4423052 | 0.75 | GRIN2C (0.57) | GRIN2CKMT2AMEN1MTNR1BLMNA | |
| SCHEMBL4418256 | 0.74 | KMT2A (0.52) | GRIN2CKMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1489071-A1 | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators | 4SC AG (DE) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | GRIN2C 567/4885KMT2A 1243/4885MEN1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.